Mankind Pharma543904Credit rating maintained/reaffirmed
Crisil AA+/Stable reaffirmed on Rs 2,500 crore NCDs; Rs 2,500 crore NCDs and Rs 1,500 crore CP withdrawn
By ScoutQuest · · 1 min read
CRISIL AA+Reaffirmed · CRISIL Ratings
- Rating Reaffirmed
- Crisil AA+/Stable reaffirmed on NCDs
- NCD Amount Reaffirmed
- 400 (₹ in crore) and 2,100 (₹ in crore)
- Ratings Withdrawn
- Crisil AA+/Stable on NCDs of 2,500 (₹ in crore) and Crisil A1+ on Commercial Paper of 1,500 (₹ in crore)
- Agency
- CRISIL Ratings
- Action
- Reaffirmed
Crisil AA+/Stable reaffirmed on Rs 2,500 crore NCDs; Rs 2,500 crore NCDs and Rs 1,500 crore CP withdrawn.
Also from Mankind Pharma
Q2 & H1 FY27 earnings call transcript: revenue Rs. 4,338 crores, EBITDA margin 27.1%
30 Oct 2026
Mankind Pharma investor deck: FY26 revenue crosses ₹14.2k Cr, chronic share targeted at ~50% by FY30, 70% stake in Belgian CAR-T firm ACTx
27 Oct 2026
Mankind Pharma's strong Q2 results won brokerage support, with Jefferies and Kotak retaining buy ratings
27 Oct 2026
More numbers
- NCDs reaffirmed (Crisil AA+/Stable)400 (₹ in crore)
- NCDs reaffirmed (Crisil AA+/Stable)2,100 (₹ in crore)
- NCDs withdrawn (Crisil AA+/Stable)2,500 (₹ in crore)
- Commercial Paper withdrawn (Crisil A1+)1,500 (₹ in crore)
Source: BSE · 29 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.